Published mark
Royalty Pharma plc
NASDAQ: RPRX. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:52361b75-63da-4409-82b1-fed172f2f056
- SEC CIK
- 0001802768
- Record version
- vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce, published Oct 15, 2026
- Newest evidence
- Apr 10, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Pablo LegorretaSince Feb 11, 2026
- Chair
- Not published
- Independent
- 4 / 55 directors published
- Published claims
- 223 distinct sources
- Evidence records
- 70 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 7 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
GC CHANGED
Arthur McGivern executive of Royalty Pharma plc, effective 2026-02-11.
EffectiveEffective Feb 11, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| General Counsel | Arthur McGivern | Feb 2026 | current | Source reportedE3 |
| Executive Vice President and Vice Chairman | Christopher Hite | Feb 2026 | current | Source reportedE4 |
| Chairman of the Board, Director and Chief Executive Officer | Pablo Legorreta | Feb 2026 | current | Source reportedE5 |
| Executive Vice President and Chief Financial Officer | Terrance Coyne | Feb 2026 | current | Source reportedE6 |
Board of directors
Evidence5 directors published. 4 of 5 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Catherine Engelbert | Independent | 2020 | Audit | Source reportedE2 |
| David Hodgson | Independent | 2022 | AuditAudit; Compensation · ChairCompensation, chair | Source reportedE2 |
| Gregory Norden | Independent | 2020 | Audit, chairAudit · Chair; Nominating and GovernanceNominating and Governance | Source reportedE2 |
| Pablo Legorreta | Not independent | 2020 | None published | Source reportedE2 |
| Vlad Coric, M.D. | Independent | 2025 | None published | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Gregory Norden | Gregory Norden, Catherine Engelbert, David Hodgson | Not described in the published record |
| Audit · Chair; Nominating and Governance | Not published | Gregory Norden | Not described in the published record |
| Audit; Compensation · Chair | Not published | David Hodgson | Not described in the published record |
| Compensation | David Hodgson | David Hodgson | Not described in the published record |
| Nominating and Governance | Not published | Gregory Norden | Not described in the published record |
Committee RecordAudit: Chair Gregory Norden; Members Gregory Norden (Chair); Catherine Engelbert; David Hodgson
Committee AppointmentGregory Norden: chair, Audit
Committee AppointmentCatherine Engelbert: member, Audit
Committee AppointmentDavid Hodgson: member, Audit
Committee RecordCompensation: Chair David Hodgson; Members David Hodgson (Chair)
Committee AppointmentDavid Hodgson: chair, Compensation
Committee RecordNominating and Governance: Chair not stated; Members Gregory Norden
Committee AppointmentGregory Norden: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerPablo Legorreta, Chairman of the Board, Director and Chief Executive Officer, from Feb 11, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingRPRX (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 16, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameRoyalty Pharma plc
Entity StatusPublic listing published
Published FactUS
Published FactHealthcare
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Arthur McGivernGeneral Counselcompany:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:11
- Christopher HiteExecutive Vice President and Vice Chairmancompany:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:12
- Pablo LegorretaChairman of the Board, Director and Chief Executive Officercompany:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:13
- Terrance CoyneExecutive Vice President and Chief Financial Officercompany:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:14
- Catherine EngelbertDirectorcompany:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:6
- David HodgsonDirectorcompany:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:7
- Gregory NordenDirectorcompany:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:8
- Pablo LegorretaDirectorcompany:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:9
- Vlad Coric, M.D.Directorcompany:52361b75-63da-4409-82b1-fed172f2f056:leadership_role:10
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 7 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 15, 2026. Cited by 5 Claims.
- E2sec proxy. Published Apr 10, 2026. Retrieved Jul 12, 2026. Cited by 5 Claims.
- E3sec filing. Published Feb 11, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E4sec filing. Published Feb 11, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E5sec filing. Published Feb 11, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E6sec filing. Published Feb 11, 2026. Retrieved May 5, 2026. Cited by 1 Claim.
- E7board_seats. board seats. Cited by 8 Claims.
What changed in version public-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce
vpublic-1:d751713988987e9331980363e24189ce:ro-d751713988987e9331980363e24189ce published Oct 15, 2026- Arthur McGivern executive of Royalty Pharma plc, effective 2026-02-11.
- Christopher Hite executive of Royalty Pharma plc, effective 2026-02-11.
- Pablo Legorreta executive of Royalty Pharma plc, effective 2026-02-11.
- Terrance Coyne executive of Royalty Pharma plc, effective 2026-02-11.
- Vlad Coric, M.D. seat on Royalty Pharma plc, effective 2025-01-01.
- David Hodgson seat on Royalty Pharma plc, effective 2022-01-01.
- Audit; Compensation · Chair committee of Royalty Pharma plc, effective 2022-01-01.
- David Hodgson member of Audit; Compensation · Chair, effective 2022-01-01.
- Catherine Engelbert seat on Royalty Pharma plc, effective 2020-01-01.
- Gregory Norden seat on Royalty Pharma plc, effective 2020-01-01.
- Pablo Legorreta seat on Royalty Pharma plc, effective 2020-01-01.
- Catherine Engelbert member of Audit, effective 2020-01-01.
- Audit · Chair; Nominating and Governance committee of Royalty Pharma plc, effective 2020-01-01.
- Gregory Norden member of Audit · Chair; Nominating and Governance, effective 2020-01-01.